Evidence map›Paper›PMID 38169389›Full record

ReviewJournal of nanobiotechnology2024

Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives.

He-Qin Zhan, Xiaoxun Zhang, Xu-Lin Chen, Liang Cheng, Xianwen Wang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

He-Qin Zhan *Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Xiaoxun Zhang *Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Xu-Lin ChenDepartment of Burns, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Liang ChengInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, 215123, People's Republic of China.
Xianwen WangSchool of Biomedical Engineering, Research and Engineering Center of Biomedical Materials, Anhui Medical University, Hefei, 230032, China. xianwenwang@ahmu.edu.cn.
Anhui Medical University · CNSecond Hospital of Anhui Medical University · CNSoochow University · CN

Funding

Anhui Province Natural Science Foundation 2208085QC81, 1208085MH175Basic and Clinical Cooperative Research and Promotion Program of Anhui Medical University 2021xkjT028National Natural Science Foundation of China 52202343, 82172858Research Fund of Anhui Institute of Translational Medicine 2022zhyx-C01
6 · The paper itself

Abstract

Glomerulonephritis (GN) is the most common cause of end-stage renal failure worldwide; in most cases, it cannot be cured and can only delay the progression of the disease. At present, the main treatment methods include symptomatic therapy, immunosuppressive therapy, and renal replacement therapy. However, effective treatment of GN is hindered by issues such as steroid resistance, serious side effects, low bioavailability, and lack of precise targeting. With the widespread application of nanoparticles in medical treatment, novel methods have emerged for the treatment of kidney diseases. Targeted transportation of drugs, nucleic acids, and other substances to kidney tissues and even kidney cells through nanodrug delivery systems can reduce the systemic effects and adverse reactions of drugs and improve treatment effectiveness. The high specificity of nanoparticles enables them to bind to ion channels and block or enhance channel gating, thus improving inflammation. This review briefly introduces the characteristics of GN, describes the treatment status of GN, systematically summarizes the research achievements of nanoparticles in the treatment of primary GN, diabetic nephropathy and lupus nephritis, analyzes recent therapeutic developments, and outlines promising research directions, such as gas signaling molecule nanodrug delivery systems and ultrasmall nanoparticles. The current application of nanoparticles in GN is summarized to provide a reference for better treatment of GN in the future.

Indexed as

Diabetic NephropathiesGlomerulonephritisLupus NephritisHumansKidneyNanotechnologyDiabetic nephropathyLupus nephritisNanocarrierNanotechnologyPrimary glomerulonephritisTherapy

Identifiers

PMID38169389
PMCPMC10763010
OpenAlexW4390536099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.